University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital
Search Site | Find a Doctor
Print this page
FONT SIZE
Home > Doctors > Susan Chang

Susan Chang, M.D.

Neuro-oncologist

Dr. Susan Chang, director of Neuro-Oncology, specializes in the treatment of adults with brain tumors. She also performs studies of experimental brain tumor treatments and evaluates the use of imaging techniques as treatment tools. She was the co-recipient of a SPORE grant for evaluating the role of magnetic resonance spectroscopy in diagnosing tumors and evaluating therapeutic interventions. SPORE, which stands for Specialized Programs of Research Excellence, is a program of the National Cancer Institute.

Chang received a medical degree from the University of British Columbia and completed a residency in internal medicine at Plains Health Centre in Canada and at Toronto General Hospital. She completed a fellowship in medical oncology at Princess Margaret Hospital in Toronto as well as a fellowship in neuro-oncology at the UCSF, where she later joined the faculty.

Conditions & Treatments

Clinics

Neuro-Oncology Clinic
400 Parnassus Ave., Eighth Floor
San Francisco, CA 94143
Phone: (415) 353-2966
Fax: (415) 353-2167

Hours: Monday to Friday
8 a.m. – 5 p.m.

More about Susan Chang

Education

University of British Columbia School of Medicine 1985

Residencies

Plains Health Centre/Toronto General Hospital, Internal Medicine 1990

Fellowships

University of Toronto Medical Center, Medical Oncology 1991
UCSF Medical Center, Neuro-Oncology 1995

Selected Research and Publications

  1. Estep JD, Chang SM, Bhimaraj A, Torre-Amione G, Zoghbi WA, Nagueh SF. Imaging for ventricular function and myocardial recovery on nonpulsatile ventricular assist devices. Circulation. 2012 May 8; 125(18):2265-77.
  2. Constantin A, Elkhaled A, Jalbert L, Srinivasan R, Cha S, Chang SM, Bajcsy R, Nelson SJ. Identifying malignant transformations in recurrent low grade gliomas using high resolution magic angle spinning spectroscopy. Artif Intell Med. 2012 May; 55(1):61-70.
  3. Dziurzynski K, Chang SM, Heimberger AB, Kalejta RF, McGregor Dallas SR, Smit M, Soroceanu L, Cobbs CS. Consensus on the role of human cytomegalovirus in glioblastoma. Neuro Oncol. 2012 Mar; 14(3):246-55.
  4. Ozturk-Isik E, Pirzkall A, Lamborn KR, Cha S, Chang SM, Nelson SJ. Spatial characteristics of newly diagnosed grade 3 glioma assessed by magnetic resonance metabolic and diffusion tensor imaging. Transl Oncol. 2012 Feb; 5(1):10-8.
  5. Clark AJ, Lamborn KR, Butowski NA, Chang SM, Prados MD, Clarke JL, McDermott MW, Parsa AT, Berger MS, Aghi MK. Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment. Neurosurgery. 2012 Feb; 70(2):361-70.
  6. Elkhaled A, Jalbert LE, Phillips JJ, Yoshihara HA, Parvataneni R, Srinivasan R, Bourne G, Berger MS, Chang SM, Cha S, Nelson SJ. Magnetic Resonance of 2-Hydroxyglutarate in IDH1-Mutated Low-Grade Gliomas. Sci Transl Med. 2012 Jan 11; 4(116):116ra5.
  7. Clarke JL, Chang SM. Neuroimaging: diagnosis and response assessment in glioblastoma. Cancer J. 2012 Jan; 18(1):26-31.
  8. Vogelbaum MA, Jost S, Aghi MK, Heimberger AB, Sampson JH, Wen PY, Macdonald DR, Van den Bent MJ, Chang SM. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery. 2012 Jan; 70(1):234-43; discussion 243-4.
  9. Butowski NA, Chang SM. General and neurological complications of targeted therapy. Handb Clin Neurol. 2012; 105:937-45.
  10. Li FM, Nie Q, Wang RM, Chang SM, Zhao WR, Zhu Q, Liang YK, Yang P, Zhang J, Jia HW, Fang HH. (11)C-CHO PET in optimization of target volume delineation and treatment regimens in postoperative radiotherapy for brain gliomas. Nucl Med Biol. 2012 Apr; 39(3):437-42.
  11. Lupo JM, Chuang CF, Chang SM, Barani IJ, Jimenez B, Hess CP, Nelson SJ. 7-tesla susceptibility-weighted imaging to assess the effects of radiotherapy on normal-appearing brain in patients with glioma. Int J Radiat Oncol Biol Phys. 2012 Mar 1; 82(3):e493-500.
  12. Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M. Conditional probability of survival in patients with newly diagnosed glioblastoma. J Clin Oncol. 2011 Nov 1; 29(31):4175-80.
  13. Butowski N, Chang SM, Lamborn KR, Polley MY, Pieper R, Costello JF, Vandenberg S, Parvataneni R, Nicole A, Sneed PK, Clarke J, Hsieh E, Costa BM, Reis RM, Hristova-Kazmierski M, Nicol SJ, Thornton DE, Prados MD. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro Oncol. 2011 Dec; 13(12):1331-8.
  14. Khayal IS, Vandenberg SR, Smith KJ, Cloyd CP, Chang SM, Cha S, Nelson SJ, McKnight TR. MRI apparent diffusion coefficient reflects histopathologic subtype, axonal disruption, and tumor fraction in diffuse-type grade II gliomas. Neuro Oncol. 2011 Nov; 13(11):1192-201.
  15. Clarke Dagger JL, Ennis Dagger MM, Yung WK, Chang SM, Wen PY, Cloughesy TF, Deangelis LM, Robins HI, Lieberman FS, Fine HA, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Lamborn KR, Prados MD. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol. 2011 Oct; 13(10):1118-24.
  16. Wen PY, Schiff D, Cloughesy TF, Reardon DA, Batchelor TT, Chabner BA, Flaherty K, de Groot JF, Gilbert MR, Galanis E, Chang SM, Schwartz GK, Peereboom D, Mehta MP, Yung WK, Grossman SA, Prados MD, DeAngelis LM. It is time to include patients with brain tumors in phase I trials in oncology. J Clin Oncol. 2011 Aug 20; 29(24):3211-3.
  17. Kaur G, Bloch O, Jian BJ, Kaur R, Sughrue ME, Aghi MK, McDermott MW, Berger MS, Chang SM, Parsa AT. A critical evaluation of cystic features in primary glioblastoma as a prognostic factor for survival. J Neurosurg. 2011 Oct; 115(4):754-9.
  18. de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson EF, Lieberman F, Robins HI, Mehta MP, Lassman AB, Deangelis LM, Yung WK, Chen A, Prados MD, Wen PY. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol. 2011 Jul 1; 29(19):2689-95.
  19. Hakeem A, Bhatti S, Trevino AR, Samad Z, Chang SM. Non-invasive risk assessment in patients with chronic kidney disease. J Nucl Cardiol. 2011 May; 18(3):472-85.
  20. Walker SP, Chang SM, Vera-Hernández M, Grantham-McGregor S. Early childhood stimulation benefits adult competence and reduces violent behavior. Pediatrics. 2011 May; 127(5):849-57.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions by logging on to UCSF Profiles.

Home • Terms of Use • Site Map • Contact Us       © 2002 - 2012 The Regents of The University of California